Theranos got characteristically defensive after an outside study found flaws in the company's blood tests.
The one thing that's been missing from the criticism surrounding Theranos, the multibillion dollar blood-testing startup? Data.
Theranos got characteristically defensive after an outside study found flaws in the company's blood tests.
The one thing that's been missing from the criticism surrounding Theranos, the multibillion dollar blood-testing startup? Data.
No comments:
Post a Comment